Policy

GENinCode (GENI) Unveils Groundbreaking CARDIO inCode-Score® Clinical Data at ESC Congress 2026, Reclassifying Risk in 42.6% of Patients

1 source ·1 article ·6h ago

GENinCode Plc (AIM: GENI), the AIM-listed predictive genetics firm specializing in cardiovascular disease prevention and ovarian cancer risk evaluation, has revealed preliminary clinical findings for its CARDIO inCode-Score® Coronary Artery…

Covered by 1 outlet

Kalkinemedia 1

All coverage · 1 article

Kalkine Media UK ·6h ago

GENinCode (GENI) Unveils Groundbreaking CARDIO inCode-Score® Clinical Data at ESC Congress 2026, Reclassifying Risk in 42.6% of Patients

GENinCode (GENI) Unveils Groundbreaking CARDIO inCode-Score® Clinical Data at ESC Congress 2026, Reclassifying Risk in 42.6% of Patients →

GENinCode (GENI) Unveils Groundbreaking CARDIO inCode-Score® Clinical Data at ESC Congress 2026, Reclassifying Risk in 42.6% of Patients